NEW YORK (GenomeWeb News) – Sygnis Pharma today said that it has licensed to Qiagen rights to distribute a new amplification buffer for isothermal amplification.

Sygnis, which is based in both Madrid, Spain and Heidelberg, Germany, said that the new buffer, which is used in isothermal amplification, was developed in the lab of Margarita Salas at the Center for Molecular Biology - Severo Ochoa, Autonomous University of Madrid/ Spanish National Research Council (CSIC). Terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.